Developer docs
API playgroundTry for free, no card

Search company profiles

Ovation

Full company profile

uuid0000ruv

Namestring
Ovation
Legal namestring
Ovation IO Inc
Websiteurl
ovation.io
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Ovation is a scientific data company operating a two-sided platform that combines a cloud-based Laboratory Information Management System (LIMS) for molecular diagnostic laboratories with a commercial multiomic data licensing business serving life sciences and biopharma customers. Founded in 2009 and headquartered in Portland, Maine, the company sells Ovation LIMS — a SaaS platform supporting workflows across qPCR, NGS, microarray, and mass spectrometry technologies for applications including COVID-19 testing, cancer genomics, pharmacogenomics, NIPT, and infectious disease — through direct enterprise field sales to clinical laboratories.

The company's distinctive asset is its clinicogenomic biobank of approximately 1.69 million consented samples from over 628,000 diverse U.S. patients, generated and replenished through the Ovation Research Network (ORN), a network of 21 independent clinical diagnostic laboratories that contribute remnant biospecimens and are compensated for sample use and sponsored research testing. Data assets include 30-50x whole genome sequencing, whole exome sequencing, and RNA sequencing linked to longitudinal phenotypic data from claims, EHR, and lab sources across 60+ pre-defined disease cohorts and 290+ pathogens, with tokenization via Datavant and distribution through AWS Data Exchange, Amazon Omics, and the DNAnexus Precision Health Data Cloud.

Ovation monetizes through three primary streams: (1) LIMS SaaS subscriptions (annual, quote-based) sold to molecular diagnostic labs including hospital labs, reference labs, and startups, with reported 38% throughput gains and 20-day startup implementation; (2) genomic and multiomic data licensing (subscription/per-dataset) to biopharma customers such as Moderna for applications including clinical trial site selection and biomarker discovery; and (3) research network participation payments to ORN labs. A fourth stream — consumer DNA tests and laboratory-developed tests for predicting GLP-1 therapy response, developed with PrecisionLife using a 10,000-patient dataset growing to 25,000 — is planned for H2 2026. The company is venture-backed (Borealis Ventures, StageDotO, SignalFire, Black Point Group, Madrona) with cumulative disclosed funding of approximately $34.78M, holds SOC 2 Type 1 and HIPAA certifications (2022), and operates as a private corporation following its September 2024 merger with PD Theranostics.

Short descriptiontext

Ovation is a scientific data company operating a cloud-based LIMS for molecular diagnostic laboratories paired with a clinicogenomic biobank of ~1.69 million samples from 628,000+ U.S. patients, licensing multiomic and pathogen data to biopharma customers and launching GLP-1 response genetic tests via PrecisionLife partnership in H2 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Laboratory Information Management Systems, Genomic Data Licensing, Multiomics Data Products, Molecular Diagnostics Software, Clinical Biobank Services
Industry4 codes
PRIMARYHLACAMAC
Molecular & Genomic LIMS (NGS/Bioinformatics Lab Ops)
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLAGAJAA
Laboratory Information Management Systems (LIMS)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Prepackaged Software7372
  • Services-Computer Programming, Data Processing, Etc.7370
  • Services-Commercial Physical & Biological Research8731
Product category
Genomic Data and Laboratory Information Management Software
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Genomic Data Licensing
TypeLicensing Royalties
Description

Ovation licenses its multiomic data products (whole genome sequencing, RNA sequencing, phenotypic data) to life sciences and biopharma companies for biomarker discovery, target identification, patient stratification, and drug development. Revenue is generated through data licensing fees, with datasets available for direct delivery or through partner platforms like AWS Data Exchange and DNAnexus.

ovation.io
2LIMS Software Subscription
TypeSubscription Recurring
Description

Ovation LIMS is sold as a cloud-based SaaS subscription to molecular diagnostic laboratories. The platform supports end-to-end lab operations from order entry to billing, with integrations across EMR systems, clinical interpretation platforms, and revenue cycle management tools.

ovation.io
3Research Network Participation
TypeProfessional Services
Description

Clinical laboratories in the Ovation Research Network receive payment for contributing remnant samples and performing research-related testing. Labs earn usage fees when their samples are used in research and payment for sponsored research testing projects.

ovation.io
4GLP-1 Biomarker Tests (Future)
TypeLicensing Royalties
Description

Planned revenue stream from consumer DNA tests and laboratory-developed tests (LDTs) for predicting GLP-1 drug response, developed in partnership with PrecisionLife and expected to launch in H2 2026. Tests will be available as both direct-to-consumer products and through CLIA lab partners.

ovation.io
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details2 tiers
1Enterprise LIMS subscription with customized pricing
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing not publicly disclosed; cloud-based LIMS platform with full lifecycle support from order entry to billing

ovation.io
2GLP-1 Clinicogenomic Dataset licensing
ModelSubscriptionBilling cadenceAnnual
Notes

10,000 whole genome sequenced patients available for immediate licensing; cohort expected to grow to 25,000 patients; dataset includes rich linked phenotypic data

ovation.io
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Ovation LIMS
Description

Cloud-based Laboratory Information Management System software for molecular diagnostic laboratories

ovation.io
+1 more record
Core offering1 text field

Ovation provides a cloud-based Laboratory Information Management System (LIMS) purpose-built for molecular diagnostic laboratories, together with a commercial multiomics data business that licenses consented genomic, transcriptomic, and phenotypic datasets to life sciences companies for drug discovery and development. Its Ovation Research Network of 21 independent clinical labs continuously feeds consented remnant samples into a 1.6-million-sample biobank, while partnerships with AWS, DNAnexus, and Datavant enable distribution, analysis, and tokenized data linking.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 38% increase in sample throughput for labs using Ovation LIMS
+7 more records
Product overview1 text field

Ovation offers a cloud-based molecular Laboratory Information Management System (LIMS) as its core product, complemented by the Ovation Research Network for biospecimen contribution and a commercial Data Products division offering genomic and multiomic datasets. The LIMS platform handles end-to-end laboratory operations from order entry to billing, while the Research Network enables diagnostic labs to contribute remnant samples for research. Data Products provide research-ready genomic datasets across 60+ disease cohorts, including GLP-1-specific clinicogenomic data available for licensing. The company operates as a genomic data company providing paired multiomic data solutions to accelerate precision medicine development.

Product and service5 records
1Ovation LIMS
CategoryLaboratory Information Management System (LIMS) Software
Description

Cloud-based Laboratory Information Management System purpose-built for molecular diagnostic laboratories. Supports end-to-end operations from order entry to final billing, with customizable workflows, EMR integrations (e.g., Epic), revenue cycle management integrations, clinical interpretation platform integrations (e.g., Fabric Genomics), real-time dashboards for sample tracking, and compatibility with qPCR, NGS, microarray, and mass spectrometry technologies. Sold as an annual SaaS subscription to clinical labs.

2Ovation Research Network
CategoryResearch Network / Biospecimen Contribution Program
Description

Network of 21 independent, geographically and demographically diverse U.S. clinical diagnostic laboratories that contribute consented remnant biospecimens for research. Participating labs receive usage fees when their samples are used in research and payment for sponsored research-related testing, while gaining a path to participate in real-world data opportunities.

3Genomic Data Products
CategoryMultiomic Data Licensing
Description

High-quality 30-50x whole genome sequencing data sourced from consented remnant samples linked to phenotypic data from claims, EHR, and lab real-world data sources. Drawn from a biobank of 628,000+ diverse U.S. individuals, consented for research and commercial purposes. Licensed to life sciences and biopharma customers for biomarker discovery, target identification, and patient stratification. Delivered directly or via AWS Data Exchange, Amazon Omics, and DNAnexus.

4Pathogen Data
CategoryPathogen Surveillance Data Licensing
Description

Real-world pathogen testing and sequencing data covering 290+ pathogens including COVID-19, influenza, and respiratory syncytial virus. Includes viral genomic data integrated with patient clinical and demographic data, refreshed up to hourly for near-real-time surveillance. Used by life sciences customers for vaccine and therapeutic research, vaccine trial enrollment planning, and epidemiological studies (e.g., Moderna used Ovation RSV testing data for ConquerRSV trial enrollment).

5GLP-1 Clinicogenomic Dataset
CategoryTherapeutic-Area Genomic Data Licensing
Description

Disease-specific clinicogenomic dataset of 10,000 whole-genome-sequenced patients with linked longitudinal phenotypic data, developed for GLP-1 receptor agonist (semaglutide, tirzepatide) response research, patient stratification, and clinical trial enrichment. Licensed to biopharma customers on an annual subscription basis.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-15
Description

Strategic collaboration to develop and commercialize GLP-1 response genetic tests. PrecisionLife analyzes Ovation's GLP-1 receptor agonist dataset using their AI-driven combinatorial analytics platform to identify biomarkers that predict patient response to GLP-1 therapies like semaglutide and tirzepatide. Phase 1 identified 2,500+ genetic signatures in 4,600 patients. Phase 2 expanding to 25,000 patients. Plans include consumer DNA test and LDT launch in H2 2026.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-03-20
Description

Partnership to deliver integrated multiomics data and analysis solutions. Ovation's IBD omics data is combined with DNAnexus Precision Health Data Cloud platform, enabling researchers to seamlessly integrate, analyze, and interpret complex biological datasets. Companies presented jointly at the 2nd Precision Medicine in IBD Summit.

Strategic tierCoreTypeTechnology or Integration
Description

AWS serves as the primary cloud infrastructure for Ovation's data storage and delivery. Ovation's genomic and pathogen data is available on AWS Data Exchange. The companies partner on data delivery via Amazon Omics for variant storage and analysis, with data automatically importable into data lakes using AWS Step Functions and Lake Formation.

Strategic tierCoreTypeTechnology or Integration
Description

Partnership for data tokenization and linking services. Datavant's common tokenization mechanisms enable Ovation to link deep genomic data to phenotypic data from claims, EHR, and lab real-world data sources. Joint webinar presented on linking genomic and phenotypic data to understand the patient journey.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Ovation Research Network participates in the NIH Rapid Acceleration of Diagnostics (RADx) Tech program. Ovation provides real-world pathogen surveillance data including COVID-19 variant genotyping. Results contributed to the Rosalind Tracker public dashboard. Ovation's involvement expanded the platform's geographic reach to rural and underserved populations.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cloud-based informatics platform serving biotech R&D and increasingly molecular diagnostic labs with structured LIMS-like workflows. Directly comparable as a SaaS lab informatics vendor pursuing biopharma customers with centralized data capture.

TypeDirect peer
Description

Multiomics data platform and Precision Health Data Cloud partner of Ovation, serving life sciences customers with genomic data storage, analysis, and cohort delivery. Directly comparable as a partner-and-occasionally-competitor in the genomic data delivery layer.

TypeBroad incumbent
Description

Long-standing enterprise LIMS vendor with deep penetration across regulated laboratories including molecular diagnostics. Comparable as the incumbent LIMS alternative Ovation competes against for replacement and new-lab deals.

TypeDirect peer
Description

AI-driven combinatorial analytics company co-developing GLP-1 response biomarkers with Ovation using its genomics dataset. Directly comparable as a strategic partner whose analytics layer could be applied to similar clinicogenomic assets elsewhere.

5Sapio Sciences
TypeDirect peer
Description

Cloud LIMS and lab informatics provider targeting molecular diagnostics and clinical labs with configurable workflows. Closely comparable as a similarly-sized LIMS challenger competing in the same molecular lab segment.

TypeEmerging player
Description

Health data tokenization and linkage platform used by Ovation to connect genomic and phenotypic data; also licenses de-identified real-world data to life sciences. Comparable as an adjacent data infrastructure peer in the same biopharma go-to-market.

TypeBroad incumbent
Description

Illumina's genomics cloud platform for sample-to-analysis workflows, used widely by molecular diagnostic labs and integrated with its sequencing instruments. Comparable as the dominant sequencing-adjacent informatics environment Ovation must integrate with rather than displace.

TypeDirect peer
Description

Genomics research and diagnostics provider offering curated multiomic datasets and lab services to biopharma globally. Comparable as a competing genomic-data licensor targeting the same biomarker discovery and patient stratification buyers.

TypeDirect peer
Description

Genomic and clinical data platform offering consented cohort data and analytics services to biopharma. Comparable as a direct genomic data licensing peer with similar clinicogenomic cohort offerings.

TypeBroad incumbent
Description

Enterprise bioinformatics platform for omics data management and analysis across pharma R&D and translational workflows. Comparable as a larger incumbent in life science informatics competing for similar biopharma IT budgets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration15 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ovation

Genomic Data and Laboratory Information Management Softwareovation.io

Ovation is a scientific data company operating a cloud-based LIMS for molecular diagnostic laboratories paired with a clinicogenomic biobank of ~1.69 million samples from 628,000+ U.S. patients, licensing multiomic and pathogen data to biopharma customers and launching GLP-1 response genetic tests via PrecisionLife partnership in H2 2026.

What Ovation does

Ovation is a scientific data company operating a two-sided platform that combines a cloud-based Laboratory Information Management System (LIMS) for molecular diagnostic laboratories with a commercial multiomic data licensing business serving life sciences and biopharma customers. Founded in 2009 and headquartered in Portland, Maine, the company sells Ovation LIMS — a SaaS platform supporting workflows across qPCR, NGS, microarray, and mass spectrometry technologies for applications including COVID-19 testing, cancer genomics, pharmacogenomics, NIPT, and infectious disease — through direct enterprise field sales to clinical laboratories.

The company's distinctive asset is its clinicogenomic biobank of approximately 1.69 million consented samples from over 628,000 diverse U.S. patients, generated and replenished through the Ovation Research Network (ORN), a network of 21 independent clinical diagnostic laboratories that contribute remnant biospecimens and are compensated for sample use and sponsored research testing. Data assets include 30-50x whole genome sequencing, whole exome sequencing, and RNA sequencing linked to longitudinal phenotypic data from claims, EHR, and lab sources across 60+ pre-defined disease cohorts and 290+ pathogens, with tokenization via Datavant and distribution through AWS Data Exchange, Amazon Omics, and the DNAnexus Precision Health Data Cloud.

Ovation monetizes through three primary streams: (1) LIMS SaaS subscriptions (annual, quote-based) sold to molecular diagnostic labs including hospital labs, reference labs, and startups, with reported 38% throughput gains and 20-day startup implementation; (2) genomic and multiomic data licensing (subscription/per-dataset) to biopharma customers such as Moderna for applications including clinical trial site selection and biomarker discovery; and (3) research network participation payments to ORN labs. A fourth stream — consumer DNA tests and laboratory-developed tests for predicting GLP-1 therapy response, developed with PrecisionLife using a 10,000-patient dataset growing to 25,000 — is planned for H2 2026. The company is venture-backed (Borealis Ventures, StageDotO, SignalFire, Black Point Group, Madrona) with cumulative disclosed funding of approximately $34.78M, holds SOC 2 Type 1 and HIPAA certifications (2022), and operates as a private corporation following its September 2024 merger with PD Theranostics.

Ovation firmographics

Firmographics
Name
Ovation
Legal name
Ovation IO Inc
Website
https://ovation.io
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Ovation is a scientific data company operating a cloud-based LIMS for molecular diagnostic laboratories paired with a clinicogenomic biobank of ~1.69 million samples from 628,000+ U.S. patients, licensing multiomic and pathogen data to biopharma customers and launching GLP-1 response genetic tests via PrecisionLife partnership in H2 2026.
Ownership category
akta.pro rank

Ovation industry classification

Industry
Product category
Genomic Data and Laboratory Information Management Software
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACAMAC
Molecular & Genomic LIMS (NGS/Bioinformatics Lab Ops)
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLAGAJAA
Laboratory Information Management Systems (LIMS)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Laboratory Information Management Systems
  • Genomic Data Licensing
  • Multiomics Data Products
  • Molecular Diagnostics Software
  • Clinical Biobank Services

Where Ovation is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ovation business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Genomic Data Licensing: Ovation licenses its multiomic data products (whole genome sequencing, RNA sequencing, phenotypic data) to life sciences and biopharma companies for biomarker discovery, target identification, patient stratification, and drug development. Revenue is generated through data licensing fees, with datasets available for direct delivery or through partner platforms like AWS Data Exchange and DNAnexus.
  2. LIMS Software Subscription: Ovation LIMS is sold as a cloud-based SaaS subscription to molecular diagnostic laboratories. The platform supports end-to-end lab operations from order entry to billing, with integrations across EMR systems, clinical interpretation platforms, and revenue cycle management tools.
  3. Research Network Participation: Clinical laboratories in the Ovation Research Network receive payment for contributing remnant samples and performing research-related testing. Labs earn usage fees when their samples are used in research and payment for sponsored research testing projects.
  4. GLP-1 Biomarker Tests (Future): Planned revenue stream from consumer DNA tests and laboratory-developed tests (LDTs) for predicting GLP-1 drug response, developed in partnership with PrecisionLife and expected to launch in H2 2026. Tests will be available as both direct-to-consumer products and through CLIA lab partners.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise LIMS subscription with customized pricing
SubscriptionAnnualGLP-1 Clinicogenomic Dataset licensing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Ovation product offering

Product offering

Core offering

Ovation provides a cloud-based Laboratory Information Management System (LIMS) purpose-built for molecular diagnostic laboratories, together with a commercial multiomics data business that licenses consented genomic, transcriptomic, and phenotypic datasets to life sciences companies for drug discovery and development. Its Ovation Research Network of 21 independent clinical labs continuously feeds consented remnant samples into a 1.6-million-sample biobank, while partnerships with AWS, DNAnexus, and Datavant enable distribution, analysis, and tokenized data linking.

Product overview

Ovation offers a cloud-based molecular Laboratory Information Management System (LIMS) as its core product, complemented by the Ovation Research Network for biospecimen contribution and a commercial Data Products division offering genomic and multiomic datasets. The LIMS platform handles end-to-end laboratory operations from order entry to billing, while the Research Network enables diagnostic labs to contribute remnant samples for research. Data Products provide research-ready genomic datasets across 60+ disease cohorts, including GLP-1-specific clinicogenomic data available for licensing. The company operates as a genomic data company providing paired multiomic data solutions to accelerate precision medicine development.

Differentiator

Problem solved

Functional benefit

Brands

  • Ovation LIMS: Cloud-based Laboratory Information Management System software for molecular diagnostic laboratories
  • Ovation Research Network (ORN)

Products and services

  • Ovation LIMS Cloud-based Laboratory Information Management System purpose-built for molecular diagnostic laboratories. Supports end-to-end operations from order entry to final billing, with customizable workflows, EMR integrations (e.g., Epic), revenue cycle management integrations, clinical interpretation platform integrations (e.g., Fabric Genomics), real-time dashboards for sample tracking, and compatibility with qPCR, NGS, microarray, and mass spectrometry technologies. Sold as an annual SaaS subscription to clinical labs.
  • Ovation Research Network Network of 21 independent, geographically and demographically diverse U.S. clinical diagnostic laboratories that contribute consented remnant biospecimens for research. Participating labs receive usage fees when their samples are used in research and payment for sponsored research-related testing, while gaining a path to participate in real-world data opportunities.
  • Genomic Data Products High-quality 30-50x whole genome sequencing data sourced from consented remnant samples linked to phenotypic data from claims, EHR, and lab real-world data sources. Drawn from a biobank of 628,000+ diverse U.S. individuals, consented for research and commercial purposes. Licensed to life sciences and biopharma customers for biomarker discovery, target identification, and patient stratification. Delivered directly or via AWS Data Exchange, Amazon Omics, and DNAnexus.
  • Pathogen Data Real-world pathogen testing and sequencing data covering 290+ pathogens including COVID-19, influenza, and respiratory syncytial virus. Includes viral genomic data integrated with patient clinical and demographic data, refreshed up to hourly for near-real-time surveillance. Used by life sciences customers for vaccine and therapeutic research, vaccine trial enrollment planning, and epidemiological studies (e.g., Moderna used Ovation RSV testing data for ConquerRSV trial enrollment).
  • GLP-1 Clinicogenomic Dataset Disease-specific clinicogenomic dataset of 10,000 whole-genome-sequenced patients with linked longitudinal phenotypic data, developed for GLP-1 receptor agonist (semaglutide, tirzepatide) response research, patient stratification, and clinical trial enrichment. Licensed to biopharma customers on an annual subscription basis.

Quantifiable outcome

  • 38% increase in sample throughput for labs using Ovation LIMS
  • +7 more outcomes

Companies that use Ovation

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Ovation technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration15 records

AI capability5 records

Feature5 records

Ovation partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and flagship.

  • PrecisionLifecoreStrategic or Co-development Partner · 15 April 2026Strategic collaboration to develop and commercialize GLP-1 response genetic tests. PrecisionLife analyzes Ovation's GLP-1 receptor agonist dataset using their AI-driven combinatorial analytics platform to identify biomarkers that predict patient response to GLP-1 therapies like semaglutide and tirzepatide. Phase 1 identified 2,500+ genetic signatures in 4,600 patients. Phase 2 expanding to 25,000 patients. Plans include consumer DNA test and LDT launch in H2 2026.
  • DNAnexuscoreTechnology or Integration · 20 March 2024Partnership to deliver integrated multiomics data and analysis solutions. Ovation's IBD omics data is combined with DNAnexus Precision Health Data Cloud platform, enabling researchers to seamlessly integrate, analyze, and interpret complex biological datasets. Companies presented jointly at the 2nd Precision Medicine in IBD Summit.
  • Amazon Web Services (AWS)coreTechnology or IntegrationAWS serves as the primary cloud infrastructure for Ovation's data storage and delivery. Ovation's genomic and pathogen data is available on AWS Data Exchange. The companies partner on data delivery via Amazon Omics for variant storage and analysis, with data automatically importable into data lakes using AWS Step Functions and Lake Formation.
  • DatavantcoreTechnology or IntegrationPartnership for data tokenization and linking services. Datavant's common tokenization mechanisms enable Ovation to link deep genomic data to phenotypic data from claims, EHR, and lab real-world data sources. Joint webinar presented on linking genomic and phenotypic data to understand the patient journey.
  • NIH RADx Tech Variant Task ForceflagshipStrategic or Co-development PartnerOvation Research Network participates in the NIH Rapid Acceleration of Diagnostics (RADx) Tech program. Ovation provides real-world pathogen surveillance data including COVID-19 variant genotyping. Results contributed to the Rosalind Tracker public dashboard. Ovation's involvement expanded the platform's geographic reach to rural and underserved populations.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Ovation competitors and assessment

Company assessment

Direct peers

  • Benchling: Cloud-based informatics platform serving biotech R&D and increasingly molecular diagnostic labs with structured LIMS-like workflows. Directly comparable as a SaaS lab informatics vendor pursuing biopharma customers with centralized data capture.
  • DNAnexus: Multiomics data platform and Precision Health Data Cloud partner of Ovation, serving life sciences customers with genomic data storage, analysis, and cohort delivery. Directly comparable as a partner-and-occasionally-competitor in the genomic data delivery layer.
  • PrecisionLife: AI-driven combinatorial analytics company co-developing GLP-1 response biomarkers with Ovation using its genomics dataset. Directly comparable as a strategic partner whose analytics layer could be applied to similar clinicogenomic assets elsewhere.
  • Sapio Sciences: Cloud LIMS and lab informatics provider targeting molecular diagnostics and clinical labs with configurable workflows. Closely comparable as a similarly-sized LIMS challenger competing in the same molecular lab segment.
  • MedGenome: Genomics research and diagnostics provider offering curated multiomic datasets and lab services to biopharma globally. Comparable as a competing genomic-data licensor targeting the same biomarker discovery and patient stratification buyers.
  • Genuity Science: Genomic and clinical data platform offering consented cohort data and analytics services to biopharma. Comparable as a direct genomic data licensing peer with similar clinicogenomic cohort offerings.

Broad incumbents

  • LabWare: Long-standing enterprise LIMS vendor with deep penetration across regulated laboratories including molecular diagnostics. Comparable as the incumbent LIMS alternative Ovation competes against for replacement and new-lab deals.
  • Illumina BaseSpace Sequence Hub: Illumina's genomics cloud platform for sample-to-analysis workflows, used widely by molecular diagnostic labs and integrated with its sequencing instruments. Comparable as the dominant sequencing-adjacent informatics environment Ovation must integrate with rather than displace.
  • Genedata: Enterprise bioinformatics platform for omics data management and analysis across pharma R&D and translational workflows. Comparable as a larger incumbent in life science informatics competing for similar biopharma IT budgets.

Emerging players

  • Datavant: Health data tokenization and linkage platform used by Ovation to connect genomic and phenotypic data; also licenses de-identified real-world data to life sciences. Comparable as an adjacent data infrastructure peer in the same biopharma go-to-market.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ovation social profiles

Digital presence

Ovation compliance and trust

Trust signal

Compliance2 records

Ovation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ovation leadership team

Management profile

Number of profiles

Profiles9 records

Ovation subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Ovation funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ovation M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ovation

What does Ovation do?

Ovation provides a cloud-based Laboratory Information Management System (LIMS) purpose-built for molecular diagnostic laboratories, together with a commercial multiomics data business that licenses consented genomic, transcriptomic, and phenotypic datasets to life sciences companies for drug discovery and development. Its Ovation Research Network of 21 independent clinical labs continuously feeds consented remnant samples into a 1.6-million-sample biobank, while partnerships with AWS, DNAnexus, and Datavant enable distribution, analysis, and tokenized data linking.

Is Ovation a public or private company?

Ovation is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ovation founded?

Ovation was founded in 2017. It employs 11 to 50 people.

Where is Ovation based?

Ovation is headquartered in Cambridge, United States, in the North America region.

How does Ovation make money?

Four revenue lines are on record. Genomic Data Licensing is the primary driver. The others are LIMS Software Subscription, research Network Participation and GLP-1 Biomarker Tests (Future).

Who are Ovation's main competitors?

Direct peers on record are Benchling, DNAnexus, PrecisionLife, Sapio Sciences, MedGenome and Genuity Science. Broad incumbents are LabWare, Illumina BaseSpace Sequence Hub and Genedata. Datavant is listed as an emerging player.

Does Ovation have an API?

Yes. Ovation LIMS offers HL7 and API integrations for EMR connectivity supporting high-volume providers. The platform includes industry-leading laboratory interoperability solutions through partner systems. Each Ovation client has a designated Integrations Lead to support coordination testing with outside systems and monitoring ongoing connection integrity.

What industry is Ovation in?

Ovation's product category is Genomic Data and Laboratory Information Management Software. Its primary akta.pro industry code is HLACAMAC, Molecular & Genomic LIMS (NGS/Bioinformatics Lab Ops), with a secondary code of HLAGAJAA, Laboratory Information Management Systems (LIMS). Its NAICS code is 5417 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InsideprecisionmedicineDNA Tests to Predict GLP-1 Drug Response to Launch in 2026PrecisionLife and Ovation.io have signed a commercialization agreement to launch GLP-1 response genetic tests by 2026, available as both direct-to-consumer and laboratory-developed tests. The companies identified combinatorial biomarker signatures that can quantitatively predict which patients will respond to GLP-1 therapies like semaglutide and tirzepatide, and sustain that response over time. The tests aim to help patients, providers, and payors make more informed decisions about GLP-1 drug selection and coverage, while also offering drug developers tools for patient stratification in clinical trials.PR NewswirePrecisionLife and Ovation ink collaboration agreement to launch GLP-1 stratification LDT and consumer GLP-1 DNA test in H2 2026Ovation.io and PrecisionLife announced a collaboration agreement to commercialize outputs from PrecisionLife's analysis of Ovation's GLP-1 receptor agonist dataset, with plans to launch a consumer DNA test and laboratory developed test in H2 2026. The companies have identified distinct quantitative markers for glycemic control that are different from those for weight loss, along with novel biological mechanisms associated with treatment response. The partners aim to enable more precise matching of patients to GLP-1 therapies and reduce unnecessary treatment costs by identifying which patients are most likely to respond.MarketsandMarkets21 Leading Laboratory Information Management System Companies Shaping the Market Landscape Through 2030A market research analysis profiles 21 leading companies in the Laboratory Information Management System (LIMS) market, highlighting their technical innovations and strategic focus areas as drivers of the evolving laboratory operations landscape through 2030. The LIMS market is described as being shaped by advances in automation, cloud integration, artificial intelligence, and data analytics. Each company entry focuses on their specific platform capabilities, target industries, and market positioning rather than reporting on specific corporate events or developments.PR NewswirePrecisionLife and Ovation identify first potential genetic biomarkers to quantitatively predict GLP-1 efficacy responsePrecisionLife and Ovation.io completed Phase 1 of their collaboration to develop genetic biomarkers predicting patient response to GLP-1 receptor agonist therapies, identifying over 2,500 genetic signatures mapped to 1,100 genes with 15 main genetic mechanisms driving drug efficacy. The biomarkers were identified in 100% of the 4,600 patients studied, with findings applicable to approximately 50% of patients who typically discontinue GLP-1 treatment within 12 months. The companies are now expanding into Phase 2, scaling the dataset to up to 25,000 patients to validate efficacy signals and identify safety and tolerability markers, with potential to inform payor reimbursement policies.OvationONCare Alliance and Ovation.io Partner to Create a Multi-Omics Database and Biobank to Accelerate Biomarker Discovery in OncologyONCare Alliance and Ovation.io have partnered to create a multi-omics database and biobank aimed at accelerating biomarker discovery in oncology. The collaboration combines real-world clinical EMR data from 32 independent oncology practices with research-grade multi-omics data to support precision medicine. This initiative focuses on collecting serial samples from breast cancer and non-small cell lung cancer patients to generate longitudinal datasets for drug discovery.Precisionmedicineonlinepayor coverage Precision Oncology NewsOvation.io and PrecisionLife have partnered to develop a pharmacogenomic (PGx) test for GLP-1 weight-loss drugs, aimed at helping payors and healthcare systems identify patients likely to respond. Separately, an analysis by Tufts researchers found that half of US commercial health plans impose additional coverage limits on gene and cell therapies beyond their approved indications.PR NewswireLucius Partners Portfolio Company, PD Theranostics, Completes its Merger with Ovation.io Creating a Multiomic Data Company Which Owns a Unique Population-Scale Biobank of Disease-Specific BiospecimensPD Theranostics and Ovation.io completed their merger on September 5, 2024, to form a new multiomic data company combining genomic sequencing with cellular imaging technologies. The merged entity manages a biobank of over 1.6 million disease-specific biospecimens from more than 600,000 patients to accelerate drug discovery and clinical decision-making. This strategic combination aims to create industry-leading datasets that link genetic information with spatial and pathological context for research in diseases such as cancer and inflammatory bowel disease.PrwebPreparing for the Return of Travelers, Ovation Travel Group Develops "Standing with You" Kits for Safer TravelsOvation Travel Group is launching complimentary 'Standing with You' kits for its corporate and leisure clients, available upon request. Each kit includes a face mask, hand sanitizer, disinfecting wipes, tissues, and a thermometer. The company aims to enhance traveler safety and reduce anxiety as states reopen.PrwebOvation Fertility Scientists Present Research at UEARS in Cairo, EgyptTwo Ovation Fertility scientists will present research and chair sessions at the 5th Upper Egypt Assisted Reproduction Conference in Cairo, Egypt, on February 19-20, 2020. Their talks cover artificial intelligence for embryo selection and best practices for cryostorage of reproductive materials.